CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, and Family Medicine Specialists (FMS), a ...

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, and Family Medicine Specialists (FMS), ...

Cardio Diagnostics said the final gapfill payment rate of $854 for both tests is an increase from the preliminary gapfill ...

Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, is making progress in gaining broad access to Medicare reimbursement for its Epi+Gen CHD™ and ...

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics, Inc, a biotechnology company making cardiovascular disease prevention and early detection more accessible, personalized and precise, announces the launch ...

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced the launch of PrecisionCHD™, an ...

Obtaining the payment rates marks a key milestone in gaining broad access to Medicare reimbursement. CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (CDIO) (Nasdaq: CDIO), an AI-powered ...

Cardio Diagnostics announced that CMS has issued a final gapfill payment rate of $854 for both the Epi+Gen CHD™ and PrecisionCHD™ tests.

Cardio Diagnostics Enters Into an Agreement with AGEPHA Pharma to Advance Precision Assessment and Management of Inflammation Associated with Coronary Heart Disease AGEPHA Pharma will supply LODOCO® ...

NEW YORK, Aug. 31 (UPI) --A single blood test that measures inflammation and fat can predict women's risk for cardiovascular disease 30 years later, a new Harvard study suggests. The findings, ...